Federated Hermes, Inc. Crispr Therapeutics Ag Transaction History

Federated Hermes, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$60.67 - $89.12 $3.67 Million - $5.39 Million	-60,494 Reduced 11.91%	447,606 $30.5 Million
Q3 2023 Nov 13, 2023	SELL	$45.39 - $59.0 $29,866 - $38,822	-658 Reduced 0.13%	508,100 $23.1 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $4.41 Million - $6.05 Million	-72,160 Reduced 12.42%	508,758 $33.2 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $594,956 - $955,150	-5,900 Reduced 1.01%	580,918 $94 Million
Q1 2021 May 13, 2021	SELL	$110.72 - $210.04 $5.57 Million - $10.6 Million	-50,282 Reduced 7.89%	586,818 $71.5 Million
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $10.4 Million - $22.7 Million	-131,150 Reduced 17.07%	637,100 $97.5 Million
Q3 2020 Nov 12, 2020	SELL	$78.5 - $100.64 $24.3 Million - $31.2 Million	-309,750 Reduced 28.73%	768,250 $64.3 Million
Q1 2020 May 13, 2020	SELL	$33.68 - $62.53 $6.19 Million - $11.5 Million	-183,700 Reduced 14.56%	1,078,000 $45.7 Million
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $14.7 Million - $29.3 Million	400,037 Added 46.43%	1,261,700 $76.8 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $1.23 Million - $1.58 Million	30,000 Added 3.61%	861,663 $35.3 Million
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $2.39 Million - $3.25 Million	67,400 Added 8.82%	831,663 $39.2 Million
Q3 2018 Nov 13, 2018	BUY	$44.35 - $65.71 $5.89 Million - $8.73 Million	132,863 Added 21.04%	764,263 $33.9 Million
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $26.9 Million - $46.5 Million	631,400 New	631,400 $37.1 Million

494

64.3M

1.68M

1.95M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.88B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.